Evolving epidemiologic trends in nonclear cell renal cell cancer: An analysis of the California cancer registry

Urology

Volumn 82, Issue 4, 2013, Pages 840-845

  Pai, Ashok ^a,b   Brunson, Ann ^a,b   Brown, Monica ^a,b   Pan, Chong Xian ^a,b   Lara Jr , Primo N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Cancer Registry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER REGISTRY; CAUSE SPECIFIC SURVIVAL; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; HISPANIC; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SOCIAL STATUS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84884935924     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.07.020     Document Type: Article

References (18)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. M.L. Nickerson, Y. Jaeger, and Y. Shi Improved identification of von-Hippel-Lindau gene alterations in clear cell renal tumors Clin Cancer Res 14 2008 4726 4734
3. W. Linehan, R. Srinivasan, and L. Schmidt The genetic basis of kidney cancer: a metabolic disease Nat Rev Urol 7 2010 277 285
4. B. Peruzzi, and D.P. Bottaro Targeting the c-met signaling pathway in cancer Clin Cancer Res 15 2006 3657 3660
5. V. Launonen, O. Vierimaa, and M. Kiuru Inherited susceptibility to uterine leiomyomas and renal cell cancer Proc Natl Acad Sci U S A 98 2001 3387 3392
6. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
7. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
8. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
9. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
10. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
11. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2278
12. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
13. D. Shek, B. Tomlinson, and M. Brown Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients Clin Genitourin Cancer 10 2012 93 98
14. Harris DHA, M.E.; Snipes K.P. Research Utilizing the California Cancer Registry. In: California Department of Public Health CSS, ed. Sacramento, CA 2007, 12-13.
15. F.L. Greene American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual 6th ed. 2002 Springer-Verlag New York 15 16
16. A. Lopez-Beltran, M. Scarpelli, and R. Montironi 2004 WHO Classification of Renal Tumors in Adults Eur Urol 49 2006 798 805
17. M. Waldert, A. Haitel, and M. Marberger Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC BJU Int 102 2008 1381 1384
18. Lynch CF, West M, Davila JA et al. Cancers of the kidney and renal pelvis (Chapter 24); in Ries L, et al, eds: SEER Survival Monograph, 193-202.